# A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice

> **NCT03659669** · — · SUSPENDED · sponsor: **AbbVie** · enrollment: 272 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03659669
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** SUSPENDED
- **Start date:** 2019-02-10
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 272 (ESTIMATED)
- **Why stopped:** Strategic considerations
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03659669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03659669, "A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03659669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*